The COVID-19 vaccine being developed by AstraZeneca could receive emergency use approval from British regulators on Monday or Tuesday and begin rolling out to British citizens in the first week of 2021.
As the company submitted the data and results of its vaccine to the British regulators last week, and CEO of the company, Pascal Soriot, says that the results will show the effectiveness of the vaccine by 95% in preventing infection with the Corona virus, that is, as effective as the Pfizer and BioNTech vaccines.
After the announcement by AstraZeneca, its shares gained 4% in trading on Monday to $50.28, and Soriot added that the vaccine is likely to provide protection against the new strain of the virus spreading in the UK, which is more contagious than its predecessor.
AstraZeneca’s release of an effective vaccine against the Corona virus will speed up the process of delivering vaccines to people around the world, because its two-dose vaccine does not require storage conditions at very low temperature, unlike vaccines that work with mRNA technology developed by Moderna, Pfizer and BioNTech, where Storage of AstraZeneca vaccine requires refrigeration at 36 to 46 degrees Fahrenheit and can be stored for at least six months.
The United States has a contract with the company to secure 300 million doses of the vaccine, which is more than it has ordered from Moderna, Pfizer and BioNTech.